Niacin and aspirin

PreclinicalSmall molecule

EEastern Virginia Medical School

Niacin and aspirin is one of 13 small molecule programs targeting Flushing. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

FlushingActive, not recruiting

FlushingPreclinical

Active, not recruiting

Competition

Competitive Landscape

24 competitors in Flushing

#DrugCompanyPhaseTrials

Xylocaine

MMEDRx USA, Inc.

Approved

1 2

Niacor

AbbVie

Phase 3

2 3

Botulinum Toxin a

GSK

Approved

—4

Hcg

Changchun GeneScience Pharmaceutical Co., Ltd.

Approved

1 5

Heparin Sodium

BBaxter Healthcare Corporation

Phase 3

2 6

BG00012

Biogen

Phase 3

1 7

Nitrostat

VViatris Specialty LLC

Phase 2

1 8

Alphagan

AbbVie

Phase 1

1 9

Bayer Aspirin

Bayer

Preclinical

3 10

AMG 334

DDanish Headache Center

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Flushing1 trial

Role of Prostaglandins on Niacin-Induced Flushing

Completed·—··NCT00930839·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Niacin and aspirin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Niacin and aspirin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Niacin and aspirin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eastern Virginia Medical School company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: EEastern Virginia Medical School

Niacin and aspirin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Flushing1 trial

References

Drug Info

Quick Facts

Related News